摘要:
Advanced glycation endproducts (AGEs) have been implicated in the pathogenesis of a variety of debilitating diseases such as diabetes, atherosclerosis, Alzheimer's and rheumatoid arthritis, as well as in the normal aging process. Five compounds are here reported to be active in breaking AGE-protein cross-links. These compounds are L-bis-[4-(4-chlorobenzamido-phenoxyisobutyryl)cystine] (LR20); 4-(3,5-dichlorophenylureido)phenoxyisobutyryl-1-amido-cyclohexane-1-carboxylic acid (LR23); methylene bis [4,4'-(2-chlorophenylureido-phenoxyisobutyric acid)] (LR90); 5-aminosalicylic acid (5-ASA); and metformin. These compounds may be used to reverse the debilitating effects of those diseases in which AGEs are formed.
摘要:
A remedy for neurodegenerative diseases containing zonisamide or an alkali metal salt thereof as the active ingredient and usable for preventing and remedying mammalian (including human) neurodegenerative diseases such as Parkinson's disease, Huntington's disease, choreic syndrome and dystonic syndrome.
摘要:
The use of at least one ligand selected from an alpha -RAR receptor-specific agonist ligand and a gamma -RAR receptor-specific antagonist ligand to prepare a pharmaceutical composition for reducing the rate of apoptosis in at least one cell population. The composition is particularly suitable for treating a disease or disorder related to an excessive rate of apoptosis in at least one cell population.
摘要:
The present invention provides a method of treating depression, mood swings, or Alzheimer's disease in a patient in need of such treatment by administering a selective estrogen receptor modulating compound of formula (a), in which R?1 and R2¿ are independently hydroxy and alkoxy of one to four carbon atoms; and R?3 and R4¿ are independently methyl or ethyl, or R?3 and R4¿, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl-pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring.
摘要:
The present invention has for its object to provide a medicinal composition comprising coenzyme Q 10 as an active ingredient, which composition features an enhanced absorption after oral administration. The present invention is directed to a medicinal composition comprising coenzyme Q 10 as an active ingredient with the reduced form of coenzyme Q 10 accounting for more than 20 weight % of said coenzyme Q 10 .
摘要:
Un produit nutritif liquide destiné à des patients souffrant d'un trauma et traités en chirurgie présente une densité calorique d'environ 1,2 à 1,5 Kcal/mL ainsi qu'un rapport calorie/azote d'environ 112:1 à 145:1. Une partie du système protéique comprend une protéine partiellement digérée, et un supplément de L-arginine fournit environ 1 à 3 % des calories totales du produit. Le système de lipides présente un rapport entre l'acide linoléique et l'acide alpha linoléique situé dans une plage comprise entre environ 3,5:1 et eviron 5,5:1.
摘要:
A new compound derived from the p-chlorophenoxyacetic acid, the p-chlorophenoxyacetate of 1-aminoadamantine-2-ethanol of the following structural formula l: as well as its pharmaceutically acceptable salts, possessing properties for the treatment of various pathological conditions of the central nervous system; its method of preparation; pharmaceutical compositions containing the said compounds; and the treatment of various pathological conditions of the central nervous system with the use of the said compositions.